Many people with Ulcerative Colitis wonder whether it’s possible to have a satisfying sex life. Dr. David Rubin discusses how to address the situation with your physician and partner. Read more here.

Dr. Rubin was recently announced as one of three recipients of the 2020 Sherman Prize. Sherman Prize recipients “are outstanding individuals who consider the whole patient experience — not just the serious symptoms, but also the psychological and practical components of IBD. Their work is innovative and impactful, and goes well beyond the norm, generating positive benefits on behalf of patients, their families and caregivers, and the future trajectory of the field. They are out-of-the-box thinkers who energize others to enter the fight to overcome Crohn’s and colitis.”

Click Here to View the Full Article

Dr. David Rubin discusses advancements in Crohn’s disease treatment.

“And while there isn’t a cure for Crohn’s yet, we’ve come a long way in how we assess and treat it. Treatment used to involve trying a new medicine or therapy and waiting to see if it made you feel better. Now experts know that isn’t the best approach. Yes, we want people with Crohn’s to feel good, but that improvement doesn’t mean the disease is turned off. It’s crucial to get inflammation under control, too, and to get the disease under control. Otherwise, Crohn’s disease can cause permanent damage.”

Read more here.

Dr. Rubin discusses the three classes of biologic therapies approved for IBD. These therapies, albeit revolutionary for patient care are limited by clearance issues, need for dose escalation, and loss of response. The arrival of small molecule therapies, such as tofacitinib, a JAK inhibitor, signify a shift in treating IBD. Dr. Rubin argues that these agents may be effective for both induction and maintenance, and perhaps in combination with existing therapies as well. To view the video and read the full article click here.

The data on COVID-19 is changing rapidly and can be overwhelming. Having been on the frontlines of the pandemic, Dr. David T. Rubin, Dr. Sushila Dalal, and Dr. Miguel Regueiro break down the latest information and best practices for managing patients with IBD and COVID-19 infection or potential infection.

This podcast is available in both video and audio-only formats. This activity offers credit for physicians, nurse practitioners, and physician assistants.

Access the CMEOCast Podcast Episode

In light of the COVID-19 pandemic, Dr. Rubin has been active in informing IBD patients what we know, don’t know, and what experts suggest. This HealthCentral article covers “What People With IBD Need to Know about COVID-19”. Dr. Rubin says the general recommendation is to continue taking your medicine and to be very careful about social distancing. Read more here.

Advanced IBD Fellow Shintaro Akiyama, MD, PhD presented a Quick Shot of his abstract on pouchitis involving the rectal cuff at Crohn’s and Colitis Congress. MedPage Today reported the results in the article here and Healio reported the results here. Very proud of Dr. Akiyama and his continuing work with characterizing pouchitis.

Pritzker medical student Donald Lei’s manuscript was accepted to the American Journal of Gastroenterology. Reuters Health Information reported on the study with comments by Dr. Rubin. “Our study did in fact demonstrate significantly reduced rates of recurrence (testing positive within 8 weeks after antibiotic cessation) and although reinfection rates (testing positive more than 8 weeks after antibiotics) were also lower, this finding was not statistically significant,” he said. “The latter was mainly a statistical power issue.” Congratulations Donald!